• Mark Elliott Boulding, executive vice president and chief legal officer, sold 2,073 PTC Therapeutics common shares on Oct. 5-6.
• Sales priced at USD 64.03 per share on Oct. 5, USD 64.16 per share on Oct. 6.
• Transactions followed option exercises at USD 39.42 per share for the same 2,073 shares.
• Directly held stake ended unchanged at 105,272 shares.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PTC Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001578852-26-000024), on October 07, 2026, and is solely responsible for the information contained therein.